Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology

Alessia Pallaoro; Rustin Y. Mirsafavi; William T Culp; Gary B. Braun; Carl D. Meinhart; Martin Moskovits

doi:10.1016/j.nano.2018.03.001

Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology

Alessia Pallaoro, Rustin Y. Mirsafavi, William T Culp, Gary B. Braun, Carl D. Meinhart, Martin Moskovits

Surgical and Radiological Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Canine lower urinary tract neoplasia is a clinically important disease process that has high mortality due to late stage diagnosis and poorly durable response to treatment. Non-invasive diagnostic techniques (e.g. dipstick test, urine cytology) currently have poor diagnostic value, while more invasive tests (e.g. cystoscopy and biopsy) are costly and often require general anesthesia. We have developed and herein describe a quantitative cytological analysis method based on the use of surface-enhanced Raman spectroscopy (SERS), for identifying cancerous transitional cells in urine using SERS biotags (SBTs) carrying the peptide PLZ4 (amino acid sequence cQDGRMGFc) that targets malignant transitional cells. By analyzing the ratio of the PLZ4-SBTs to an on board control we were able to show that transitional cells had significantly higher ratios (P < 0.05) in patients diagnosed with transitional cell carcinoma (TCC) than in healthy samples.

Original language	English (US)
Pages (from-to)	1279-1287
Number of pages	9
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	14
Issue number	4
DOIs	https://doi.org/10.1016/j.nano.2018.03.001
State	Published - Jun 1 2018

Keywords

Cancer detection
Liquid biopsy
Surface enhanced Raman spectroscopy (SERS)
Transitional cell carcinoma (TCC)
Urine

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Molecular Medicine
Biomedical Engineering
Materials Science(all)
Pharmaceutical Science

Access to Document

10.1016/j.nano.2018.03.001

Fingerprint Dive into the research topics of 'Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology'. Together they form a unique fingerprint.

Cite this

Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology. / Pallaoro, Alessia; Mirsafavi, Rustin Y.; Culp, William T; Braun, Gary B.; Meinhart, Carl D.; Moskovits, Martin.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 4, 01.06.2018, p. 1279-1287.

Research output: Contribution to journal › Article › peer-review

@article{ce95c49e65934b749b4ee6474ae1c92f,

title = "Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology",

abstract = "Canine lower urinary tract neoplasia is a clinically important disease process that has high mortality due to late stage diagnosis and poorly durable response to treatment. Non-invasive diagnostic techniques (e.g. dipstick test, urine cytology) currently have poor diagnostic value, while more invasive tests (e.g. cystoscopy and biopsy) are costly and often require general anesthesia. We have developed and herein describe a quantitative cytological analysis method based on the use of surface-enhanced Raman spectroscopy (SERS), for identifying cancerous transitional cells in urine using SERS biotags (SBTs) carrying the peptide PLZ4 (amino acid sequence cQDGRMGFc) that targets malignant transitional cells. By analyzing the ratio of the PLZ4-SBTs to an on board control we were able to show that transitional cells had significantly higher ratios (P < 0.05) in patients diagnosed with transitional cell carcinoma (TCC) than in healthy samples.",

keywords = "Cancer detection, Liquid biopsy, Surface enhanced Raman spectroscopy (SERS), Transitional cell carcinoma (TCC), Urine",

author = "Alessia Pallaoro and Mirsafavi, {Rustin Y.} and Culp, {William T} and Braun, {Gary B.} and Meinhart, {Carl D.} and Martin Moskovits",

year = "2018",

month = jun,

day = "1",

doi = "10.1016/j.nano.2018.03.001",

language = "English (US)",

volume = "14",

pages = "1279--1287",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology

AU - Pallaoro, Alessia

AU - Mirsafavi, Rustin Y.

AU - Culp, William T

AU - Braun, Gary B.

AU - Meinhart, Carl D.

AU - Moskovits, Martin

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Canine lower urinary tract neoplasia is a clinically important disease process that has high mortality due to late stage diagnosis and poorly durable response to treatment. Non-invasive diagnostic techniques (e.g. dipstick test, urine cytology) currently have poor diagnostic value, while more invasive tests (e.g. cystoscopy and biopsy) are costly and often require general anesthesia. We have developed and herein describe a quantitative cytological analysis method based on the use of surface-enhanced Raman spectroscopy (SERS), for identifying cancerous transitional cells in urine using SERS biotags (SBTs) carrying the peptide PLZ4 (amino acid sequence cQDGRMGFc) that targets malignant transitional cells. By analyzing the ratio of the PLZ4-SBTs to an on board control we were able to show that transitional cells had significantly higher ratios (P < 0.05) in patients diagnosed with transitional cell carcinoma (TCC) than in healthy samples.

AB - Canine lower urinary tract neoplasia is a clinically important disease process that has high mortality due to late stage diagnosis and poorly durable response to treatment. Non-invasive diagnostic techniques (e.g. dipstick test, urine cytology) currently have poor diagnostic value, while more invasive tests (e.g. cystoscopy and biopsy) are costly and often require general anesthesia. We have developed and herein describe a quantitative cytological analysis method based on the use of surface-enhanced Raman spectroscopy (SERS), for identifying cancerous transitional cells in urine using SERS biotags (SBTs) carrying the peptide PLZ4 (amino acid sequence cQDGRMGFc) that targets malignant transitional cells. By analyzing the ratio of the PLZ4-SBTs to an on board control we were able to show that transitional cells had significantly higher ratios (P < 0.05) in patients diagnosed with transitional cell carcinoma (TCC) than in healthy samples.

KW - Cancer detection

KW - Liquid biopsy

KW - Surface enhanced Raman spectroscopy (SERS)

KW - Transitional cell carcinoma (TCC)

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=85046791238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046791238&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.03.001

DO - 10.1016/j.nano.2018.03.001

M3 - Article

C2 - 29597048

AN - SCOPUS:85046791238

VL - 14

SP - 1279

EP - 1287

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 4

ER -